CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2,292 enrolled
Drug / intervention
Medtronic Endeavor Resolute +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00617084
NCT00617084Phase 4Completed
CompareCT.gov

RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention

Medtronic Vascular·interventional·Posted Feb 15, 2008·Updated Jun 6, 2014

In Brief

A Phase 4 clinical trial evaluating Medtronic Endeavor Resolute and Abbott Xience V for Coronary Artery Disease. Completed, enrolled 2,292 participants across 1 site.

Detailed Summary

The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study. Primary objective: to compare the Medtronic Endeavor-Resolute (Zotarolimus-Eluting stent) system with the Abbott XIENCE V (Everolimus-Eluting stent) system with respect to cardiac death, myocardial infarction (not clearly attributable to a non-target vessel), Target Lesion Revascularization at 1 year in a "real world" patient population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesSwitzerland
CollaboratorsMedtronic Cardiac Rhythm and Heart Failure

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 15, 2008
Enrollment StartApr 1, 2008
Primary CompletionMay 1, 2010
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.4 years ago

Interventions

Medtronic Endeavor Resolutedevice

Medtronic Endeavor Resolute

Abbott Xience Vdevice

Abbott Xience V